Targeted immunotherapy rescues pulmonary fibrosis by against activated fibroblasts and regulating alveolar cell profile
Ontology highlight
ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a severe lung disease in the world, but has limited clinical therapies. Fibrosis maintains dynamic balance with overactivated fibroblasts. Given pulmonary cell regeneration, the lung may have self-repairing ability if fibrosis is removed by clearance of overactivated fibroblasts. The aim of the study is to evaluate therapeutic activity of transient CAR-T cells generated via a novelly designed LNP-mRNA system and address the relevant mechanism to epithelial cell polarization in a mouse model of bleomycin-induced IPF. Studies on proteomes and histology showed that fibrosis-induced ECM stiffening impaired epithelial cell polarization that limited cell’s self-healing ability. The proposed LNP-mRNA therapy eliminated overactivated fibroblasts and removed pulmonary fibrosis successfully. The decreased ECM stiffness and the improvement of extracellular environment facilitated re-establishment of cell polarity and restored the self-repairing ability of epithelial cell. Hence, LNP-mRNA treatment for IPF can recover pulmonary structure and function close to a healthy lung. This therapy shows a potential treatment for IPF patients.
INSTRUMENT(S): Orbitrap Astral
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Lung, Epithelial Cell
DISEASE(S): Pulmonary Fibrosis
SUBMITTER:
Jing Yan
LAB HEAD: Yunlong Huo
PROVIDER: PXD053333 | Pride | 2025-03-19
REPOSITORIES: Pride
ACCESS DATA